Preimplantation Genetics

 

Preimplantation Genetics Screening (PGS)

Array CGH (aCGH) is the most well-established of the new generation of preimplantation genetic screening (PGS) tests. It allows us to screen embryos for abnormalities in all 24 chromosomes before embryo transfer. It is well established that genetically normal embryos have a higher chance of implantation and the resulting pregnancies have a much lower chance of miscarriage. Performing PGS may therefore increase the chances of implantation and reduce the chances of a pregnancy loss. We work with the Cyprus Institute of Neurology and Genetics (CING) because as pioneers in the field of genetics they have been responsible for some of the most significant advances in preimplantation genetic diagnosis (PGD) especially in relation to Thalassaemia screening.

 

Preimplantation Genetic Diagnosis (PGD)

PGD is a method of screening embryos for a particular genetic disorder before they are transferred to the uterus and is now available for virtually all single gene disorders. The aim of PGD is to provide couples at high-risk of passing on an inherited disorder with an improved chance of having an unaffected pregnancy. We work with the Cyprus Institute of Neurology and Genetics (CING) because as pioneers in the field of genetics they have been responsible for some of the most significant advances in preimplantation genetic diagnosis (PGD) especially in relation to Thalassaemia screening.